Literature DB >> 27324073

Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database.

Caroline Hurault-Delarue1, Christine Damase-Michel1, Laurent Finotto2, Claudine Guitard3, Christophe Vayssière4, Jean-Louis Montastruc1, François Montastruc1, Isabelle Lacroix5.   

Abstract

Little is known about neurodevelopment of children exposed to psychotropic drugs during pregnancy. The purpose of this study was to evaluate the effects of prenatal exposure to psychotropic drugs on psychomotor development in children. This observational study used the EFEMERIS database. The database records the drugs prescribed and delivered during pregnancy and the resulting outcomes. Neurodevelopment at nine and 24 months of children born to women exposed to psychotropic drugs (anxiolytics, antidepressants, neuroleptics and anti-epileptics) during the second and/or third trimesters of pregnancy was compared to children who were not exposed to these drugs. Psychomotor development of 493 children (1.5%) exposed to psychotropic drugs during pregnancy was compared to 32 303 unexposed children. Exposure to psychotropic drugs during pregnancy was associated with an increased risk of abnormal motor development at 9 months (OR = 1.3 [1.1-2.2]) and abnormal motor and mental development at 24 months (OR = 4.8 [2.1-11.0] and OR = 2.3 [1.05-4.9]). Increased risk was observed in children born to women exposed to anti-epileptic drugs, neuroleptics or antidepressants during pregnancy. This study found a higher rate of deviation from the normal developmental milestones in children born to women exposed to psychotropic drugs during pregnancy and more particularly antidepressants, neuroleptics and anti-epileptics.
© 2016 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  EFEMERIS database; pregnancy; psychomotor development; psychotropic drugs

Mesh:

Substances:

Year:  2016        PMID: 27324073     DOI: 10.1111/fcp.12209

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  4 in total

1.  Use of Antipsychotic Drugs During Pregnancy.

Authors:  Hannah K Betcher; Catalina Montiel; Crystal T Clark
Journal:  Curr Treat Options Psychiatry       Date:  2019-01-30

2.  Signal Detection in EUROmediCAT: Identification and Evaluation of Medication-Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference.

Authors:  Alana Cavadino; Lovisa Sandberg; Inger Öhman; Tomas Bergvall; Kristina Star; Helen Dolk; Maria Loane; Marie-Claude Addor; Ingeborg Barisic; Clara Cavero-Carbonell; Ester Garne; Miriam Gatt; Babak Khoshnood; Kari Klungsøyr; Anna Latos-Bielenska; Nathalie Lelong; Reneé Lutke; Anna Materna-Kiryluk; Vera Nelen; Amanda Nevill; Mary O'Mahony; Olatz Mokoroa; Anna Pierini; Hanitra Randrianaivo; Anke Rissmann; David Tucker; Awi Wiesel; Lyubov Yevtushok; Joan K Morris
Journal:  Drug Saf       Date:  2021-05-09       Impact factor: 5.606

Review 3.  Long-term neurodevelopmental consequences of intrauterine exposure to lithium and antipsychotics: a systematic review and meta-analysis.

Authors:  Eline M P Poels; Lisanne Schrijver; Astrid M Kamperman; Manon H J Hillegers; Witte J G Hoogendijk; Steven A Kushner; Sabine J Roza
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-06-11       Impact factor: 4.785

Review 4.  [Antipsychotics during pregnancy: a systematic review].

Authors:  Thomas Hillemacher; Susanne Simen; Marie-Kathrin Rehme; Helge Frieling
Journal:  Nervenarzt       Date:  2020-09-30       Impact factor: 1.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.